Legend: drug field target field enzyme field
| Version | 2.5 | ||||||
| Creation Date | 2007-07-30 16:08:46 | ||||||
| Update Date | 2009-06-23 18:08:02 | ||||||
| Primary Accession Number | DB01438 | ||||||
| Secondary Accession Number | Not Available | ||||||
| Name | Phenazopyridine | ||||||
| Drug Type |
|
||||||
| Description | A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. [PubChem] | ||||||
| Synonyms |
|
||||||
| Brand Names |
|
||||||
| Brand Mixtures | Not Available | ||||||
| Chemical IUPAC Name | 3-phenyldiazenylpyridine-2,6-diamine | ||||||
| Chemical Formula | C11H11N5 | ||||||
| Chemical Structure | |||||||
| CAS Registry Number | 94-78-0 | ||||||
| InChI Identifier | InChI=1/C11H11N5/c12-10-7-6-9(11(13)14-10)16-15-8-4-2-1-3-5-8/h1-7H,(H4,12,13,14)/b16-15+/f/h12-13H2 | ||||||
| InChI Key | QPFYXYFORQJZEC-BKQDAPJRDQ | ||||||
| KEGG Drug | Not Available | ||||||
| KEGG Compound | C07429 ![]() |
||||||
| PubChem Compound | 4756 ![]() |
||||||
| PubChem Substance | 9633 ![]() |
||||||
| ChEBI ID | Not Available | ||||||
| PharmGKB ID | PA450898 ![]() |
||||||
| HET ID | Not Available | ||||||
| GenBank ID | Not Available | ||||||
| Drug ID Number [DIN] | 00271489 ![]() |
||||||
| RxList Link | http://www.rxlist.com/cgi/generic/phenazopyridine.htm ![]() |
||||||
| PDRhealth Link | http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/pyr1365.shtml ![]() |
||||||
| Wikipedia Link | http://en.wikipedia.org/wiki/Phenazopyridine ![]() |
||||||
| FDA Label | Not Available | ||||||
| Material Safety Data Sheet (MSDS) | |||||||
| Synthesis Reference | Not Available | ||||||
| Average Molecular Weight | 213.2385 | ||||||
| Monoisotopic Molecular Weight | 213.1014 | ||||||
| State | Solid | ||||||
| Melting Point | 139 oC | ||||||
| Experimental Water Solubility | Not Available Source: PhysProp | ||||||
| Predicted Water Solubility | 2.02e-01 mg/mL Calculated using ALOGPS | ||||||
| Experimental LogP/Hydrophobicity | Not Available Source: PhysProp | ||||||
| Predicted LogP | 2.31 Calculated using ALOGPS | ||||||
| Experimental LogS | Not Available | ||||||
| Predicted LogS | -3.02 Calculated using ALOGPS | ||||||
| Experimental Caco2 Permeability | Not Available | ||||||
| pKa/Isoelectric Point | Not Available | ||||||
| Mass Spectrum | Not Available | ||||||
| MOL File | Show | Download ![]() |
||||||
| SDF File | Show | Download ![]() |
||||||
| PDB File | Show | Download ![]() |
||||||
| 2D Structure | |||||||
| 3D Structure | |||||||
| Experimental PDB ID | Not Available | ||||||
| Isomeric SMILES | NC1=NC(N)=C(C=C1)\N=N\C1=CC=CC=C1 | ||||||
| Canonical SMILES | NC1=NC(N)=C(C=C1)N=NC1=CC=CC=C1 | ||||||
| Drug Category |
|
||||||
| ATC Codes | |||||||
| AHFS Codes |
|
||||||
| Indication | For the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. | ||||||
| Pharmacology | Phenazopyridine is a local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. | ||||||
| Mechanism of Action | Phenazopyridine's mechanism of action is not well known, and only basic information on its interaction with the body is available. It is known that the chemical has a direct topical analgesic effect on the mucosa lining of the urinary tract. | ||||||
| Absorption | Not Available | ||||||
| Toxicity | Methemoglobinemia generally follows a massive, acute overdose. | ||||||
| Protein Binding | Not Available | ||||||
| Biotransformation | Likely hepatic but also in other tissues. One of the metabolites is acetaminophen. | ||||||
| Half Life | Not Available | ||||||
| Dosage Forms |
|
||||||
| Patient Information | Show ![]() |
||||||
| Contraindications | Show ![]() |
||||||
| Interactions | Not Available | ||||||
| Drug Interactions | Not Available | ||||||
| Food Interactions |
|
||||||
| Pathways | Not Available | ||||||
| General References | |||||||
| Organisms Affected |
|
This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.